The global quantitative pathology imaging market is forecasted to be appraised at US$ 9.5 Billion by 2032, up from US$ 2.77 Billion in 2022, by advancing at a CAGR of 11.9% during the forecast period.
The sales of quantitative pathology imaging systems are on the rise as these systems help to visualize, quantify, analyze, and phenotype immune cells in situ in FFPE (formalin fixed paraffin embedded) tissue sections. The demand for quantitative pathology imaging systems is getting fueled as there is high adoption in the hospital sectors for this imaging system as they are able to screen tumor tissue microarrays (TMA tumors).
Report Attribute | Details |
---|---|
Quantitative Pathology Imaging Market Value (2022) | US$ 2.77 Billion |
Quantitative Pathology Imaging Market Anticipated Value (2032) | US$ 9.5 Billion |
Quantitative Pathology Imaging Projected Growth Rate (2022 to 2032) | 11.9% |
Quantitative pathology imaging systems have a lot of advantages as distinction, identification, and evaluation of different biomarkers and uncovering spatial settings inside a computerized work process to help scientists in settling on more sagacious choices.
There is rising adoption of quantitative pathology imaging systems as they can contribute to the analysis and basic understanding of the part of the resistant cells inside strong tumors and the tumor microenvironment. Therefore, due to all these factors, it is anticipated that the quantitative pathology imaging market is likely to witness significant growth during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
It is anticipated that the quantitative pathology imaging market is gaining momentum as a proven essential technology. The major factor driving the growth of the quantitative pathology imaging market is the specific support it is providing to education, drug development, tissue-based research, and the practice of human pathology throughout the world.
It is identified that there is an increasing need for enhancing lab efficiency and this factor is expected to drive the growth of the quantitative pathology imaging market.
It is a cutting-edge technology that is aiming towards lower laboratory costs, boosting production, increase operational efficiency, improving treatment decisions, and care for patients. These factors are bolstering the adoption of quantitative pathology imaging and serve as an influential factor in the market growth of quantitative pathology imaging systems.
Quantitative pathology imaging systems offer better visualization, reduced errors, reduced turnaround time, and improved workflow, which is further fueling the demand for quantitative pathology imaging systems in the global market. These systems have the multiplexing capacity, to detect and measure multiple weakly expressed overlapping biomarkers, along with the inclusion of an integrated inform analysis software that automatically identifies specific types of tissues using patented user-trainable algorithms developed for recognizing morphological patterns.
Clinical labs are using quantitative pathology imaging systems for remote consultations, quantitative analysis, and education. Furthermore, rising incidences of various types of cancer along with new lifestyle patterns, coupled with a growing geriatric and matured population energizes the overall growth of the quantitative pathology imaging market.
The facilitation of the right tumor microenvironment and accurate valuation of visualization characteristics of immune tumor cells are likely to drive the commercial demand for quantitative pathology imaging systems and contribute to the steady growth of the quantitative pathology imaging market.
Although there are a number of growth factors that are driving the robust expansion of the global quantitative pathology imaging market, it is also identified that some factors are likely to curb the growth of the quantitative pathology imaging market.
It is observed that the truncated approachability of the quantitative pathology imaging systems is not getting full-scale acceptance among healthcare specialists and is acting as a major restraining factor for the quantitative pathology imaging systems market growth.
There is a lack of availability of quantitative pathology imaging in the international market. The newly launched quantitative pathology imaging systems are considered an innovative technology for which reimbursements are not available, which can act as a restraint and hinder the growth of the global quantitative pathology imaging market.
It is projected that North America is likely to dominate the market share for quantitative pathology imaging systems. Currently, the North American region is cumulatively accountable for 41.6% of the total market share of quantitative pathology imaging.
Owing to the development and steady growth of preventive measures in these regions, the organizations of North America are concentrating on the natural laws to control the new medical devices launched. The growth can be attributed to the rising penetration of digital imaging in the huge economy of North America.
There are multiple research and development endeavors taken up on enhancing the framework and putting the resources into clinical examinations which are driving the acceptance and adoption of quantitative pathology imaging systems in North America as well.
At present, Europe is accountable for 24.8% of the total quantitative pathology imaging market.
Europe is projected to follow North America and is likely to have steady growth in the quantitative pathology imaging market during the forecast period. A major driver in the European region is the rise of the geriatric population and increasing chronic diseases that are expected to further propel the quantitative pathology imaging market.
There is an increasing demand for pathologists and clinicians to diagnose rising cancer cases and the development of the healthcare sector is stimulating the demand for quantitative pathology imaging systems and expanding the market size of quantitative pathology imaging systems in this region.
The start-up ecosystem in the quantitative pathology imaging market is intense with frequent innovations being made. Start-ups in the quantitative pathology imaging market are focusing on multiple additional features for further bolstering the adoption of this product on a large scale. They are making efforts to provide services that enable physicians and consumers to detect the presence of a disease or condition, segmented according to the technology used for diagnosis.
Diagnostics Tech is one of the most active sectors for investors, with overall funding of US$ 99.7 Billion in 2.7K+ companies. It is also interesting to note that more than half of the funding has been raised in the last 3 years. Some of the start-ups are Spring, EchoNous, Eko, and others.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Who are some of the Key Market Players in the Quantitative Pathology Imaging Market?
The key participants in the quantitative pathology imaging system market are Leica Microsystems, PerkinElmer Inc., and Diagnostic Instruments, Inc.
The organizations are essentially concentrating on the solid line of distribution channels and advertising to increase the expansion of quantitative pathology imaging systems in the international market. The major players are enhancing the features such as seeing from different angles and zooming in and out for better facilitation and use of the quantitative pathology imaging systems in the global market by consumers.
Report Attribute | Details |
---|---|
Growth Rate | CAGR of 11.9% from 2022 to 2032 |
Base Year for Estimation | 2021 |
Historical Data | 2016 to 2021 |
Forecast Period | 2022 to 2032 |
Quantitative Units | Revenue in US$ Million and CAGR from 2022 to 2032 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The quantitative pathology imaging market is set to grow at 11.9% through 2032.
The North American region is the leading quantitative pathology imaging market.
The quantitative pathology imaging market value is likely to reach US$ 9.5 Billion by 2032.
The healthcare sector is the key driver in the quantitative pathology imaging market.
1. Executive Summary | Quantitative Pathology Imaging Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Component Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Component Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Component Type, 2022 to 2032 5.3.1. Instruments 5.3.2. Software 5.3.3. Services 5.4. Y-o-Y Growth Trend Analysis By Component Type, 2017 to 2021 5.5. Absolute Opportunity Analysis By Component Type, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Pathology Diagnostic Laboratories 6.3.4. Research Institutes 6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021 6.5. Absolute Opportunity Analysis By End User, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 8.2.1. By Country 8.2.1.1. US 8.2.1.2. Canada 8.2.2. By Component Type 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Component Type 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Component Type 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Component Type 9.3.3. By End User 9.4. Key Takeaways 10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Component Type 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Component Type 10.3.3. By End User 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Rest of Asia Pacific 11.2.2. By Component Type 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Component Type 11.3.3. By End User 11.4. Key Takeaways 12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of Middle East and Africa 12.2.2. By Component Type 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Component Type 12.3.3. By End User 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. US 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2021 13.1.2.1. By Component Type 13.1.2.2. By End User 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2021 13.2.2.1. By Component Type 13.2.2.2. By End User 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2021 13.3.2.1. By Component Type 13.3.2.2. By End User 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2021 13.4.2.1. By Component Type 13.4.2.2. By End User 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2021 13.5.2.1. By Component Type 13.5.2.2. By End User 13.6. United Kingdom 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2021 13.6.2.1. By Component Type 13.6.2.2. By End User 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2021 13.7.2.1. By Component Type 13.7.2.2. By End User 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2021 13.8.2.1. By Component Type 13.8.2.2. By End User 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2021 13.9.2.1. By Component Type 13.9.2.2. By End User 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2021 13.10.2.1. By Component Type 13.10.2.2. By End User 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2021 13.11.2.1. By Component Type 13.11.2.2. By End User 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2021 13.12.2.1. By Component Type 13.12.2.2. By End User 13.13. GCC Countries 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2021 13.13.2.1. By Component Type 13.13.2.2. By End User 13.14. South Africa 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2021 13.14.2.1. By Component Type 13.14.2.2. By End User 13.15. Israel 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2021 13.15.2.1. By Component Type 13.15.2.2. By End User 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Component Type 14.3.3. By End User 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Leica Microsystems 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. PerkinElmer Inc. 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. SKF 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Indica Labs 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Paige 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. PathAI 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Proscia 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Hoffmann-La Roche AG 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. Charles River Laboratories 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Aiforia Technologies 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 15.1.11. Inspirata Inc. 15.1.11.1. Overview 15.1.11.2. Product Portfolio 15.1.11.3. Profitability by Market Segments 15.1.11.4. Sales Footprint 15.1.11.5. Strategy Overview 15.1.11.5.1. Marketing Strategy 15.1.12. Ibex Medical 15.1.12.1. Overview 15.1.12.2. Product Portfolio 15.1.12.3. Profitability by Market Segments 15.1.12.4. Sales Footprint 15.1.12.5. Strategy Overview 15.1.12.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports